Conference abstractPublished 25 Nov 2019
A comparative study of Ivabradine and Bisoprolol used in combination versus up titration of Bisoprolol to maximum dose in patients with systolic heart failure and left ventricular systolic dysfunction
Khyber Medical University, Pakistan
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Reduction in heart rate in patients with heart failure is related to improved cardiovascular outcomes. The primary objective of this study was to compare the therapeutic effects of Ivabradine used in combination with Bisoprolol versus up titration of Bisoprolol in South Asian population with systolic heart failure and left ventricular systolic dysfunction. Patients with systolic heart failure (n=114), LVEF 70 bpm, already on Bisoprolol 5 mg od/p.o were divided into 2 groups; each group had 57 patients randomly assigned. Group 1 (n=57) patients were up titrated to Bisoprolol 10 mg od/p.o and patients in Group 2 (n=57) received Ivabradine 5 mg b.i.d/p.o in addition to Bisoprolol 5 mg od/p.o. Blood samples for BNP level, an ECG, echocardiogram, systolic and diastolic BP were taken at selection (visit 0), after 2 weeks (visit 1), at 4 weeks (visit 2), at 12 weeks (visit 3), and finally at 24 weeks after completion of treatment for follow up of study (visit 4). There was a significant decrease in mean resting heart rate in Ivabradine group as compared to Bisoprolol group. Addition of Ivabradine also improved the heart failure symptoms with significant decrease in BNP. The effect on LVEDD and LVESD did not differ significantly between the two groups. However, a significant increase was observed in LVEF in Ivabradine group as compared to Bisoprolol group. The effect on systolic BP and diastolic BP was significantly affected by the up titration of Bisoprolol whereas neither parameter showed significant affect with the addition of Ivabradine. This study concludes that long-term reduction of heart rate with Ivabradine 5 mg b.i.d/p.o and Bisoprolol 5 mg od/p.o when used in combination has proven to improve primary efficacy endpoint, left ventricular ejection fraction, symptoms of heart failure and BNP significantly.
Subjects
CardiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Hypertension: Open Access
- SubjectCardiology
- BylineArticles whose byline prints “Sadia Akram”
